In plasma DNA from ALK-positive (ALK+) NSCLC patients receiving TKIs, integration of copy number variation (CNV) profiling with targeted panel sequencing has improved the molecular monitoring of disease, particularly in high-risk or heavily pretreated cases [59]. Here, ALK is linked to non-small cell lung carcinoma.